Cargando…

Posaconazole in the Prevention of COVID-19-associated Mucormycosis: A Concerning Contributor to the Rise in Antifungal Resistance

How to cite this article: Kayarat B, Khanna P. Posaconazole in the Prevention of COVID-19-associated Mucormycosis: A Concerning Contributor to the Rise in Antifungal Resistance. Indian J Crit Care Med 2021;25(10):1209–1210.

Detalles Bibliográficos
Autores principales:	Kayarat, Bhavana, Khanna, Puneet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Jaypee Brothers Medical Publishers 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645813/ https://www.ncbi.nlm.nih.gov/pubmed/34916761 http://dx.doi.org/10.5005/jp-journals-10071-23981

Ejemplares similares

Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management
por: Kayarat, Bhavana, et al.
Publicado: (2021)

Superadded Coinfections and Antibiotic Resistance in the Context of COVID-19: Where do We Stand?
por: Kayarat, Bhavana, et al.
Publicado: (2021)

Comments on: Rise of the phoenix: Mucormycosis in COVID-19 times
por: Singh, Awadhesh K, et al.
Publicado: (2021)

Response to comments on: Rise of the phoenix: Mucormycosis in COVID-19 times
por: Ravani, Swati A, et al.
Publicado: (2021)

COVID-19 associated Mucormycosis (CAM): Implications for perioperative physicians – A narrative review
por: Gupta, Anju, et al.
Publicado: (2023)

Role of Face Masks in the Rise of Mucormycosis Cases in India during the COVID-19 Pandemic
por: Chandan, SN
Publicado: (2021)

Comment to: “Association of COVID-19 with Rhino-Cerebral Mucormycosis: An Observational Study”
por: Vaidyanathan, Aiswarya, et al.
Publicado: (2022)

COVID-19 Associated Mucormycosis and Anbarnesa: Concerning about Important Source of Spores
por: Pourazizi, Mohsen, et al.
Publicado: (2022)

Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series
por: Soman, Rajeev, et al.
Publicado: (2022)

Prevention of mucormycosis in COVID-19 – the need of the hour
por: Ish, Pranav, et al.
Publicado: (2021)

Challenges of COVID-19 vaccination in Afghanistan: A rising concern
por: Essar, M.Y., et al.
Publicado: (2021)

Mucormycosis masquerading as an endobronchial tumor
por: Mahajan, Rajesh, et al.
Publicado: (2014)

COVID-19 Vaccine Efficacy in Liver Transplant Recipients: A Rising Concern
por: Zahid, Mariyam, et al.
Publicado: (2022)

Is Anxiety a Rising Concern during COVID-19 Pandemic among Healthcare Workers?
por: Murthy, Pooja R, et al.
Publicado: (2020)

COVID-19 and orbital mucormycosis
por: Sarkar, Sandip, et al.
Publicado: (2021)

A patient of bad obstetric history with ebsteins anomaly: Perianesthetic concerns
por: Selvaraj, Bright Jebaraj, et al.
Publicado: (2013)

Successful treatment of pulmonary mucormycosis caused by Rhizopus microsporus with posaconazole
por: Yuan, F., et al.
Publicado: (2021)

Successful treatment of cutaneous mucormycosis disseminated from pulmonary mucormycosis with liposomal amphotericin B and posaconazole
por: Ding, Xiao-Lan, et al.
Publicado: (2020)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021)

Mucormycosis in COVID-19: The Indian scenario
por: Ghosh, Ritwik, et al.
Publicado: (2022)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

The surge in Covid related mucormycosis
por: Chandra, Somesh, et al.
Publicado: (2021)

Triple challenge of diabetes, COVID-19, and mucormycosis
por: Rastogi, Ashu, et al.
Publicado: (2021)

Mucormycosis Following COVID-19 Infections: an Insight
por: Das, Srijit, et al.
Publicado: (2021)

Mucormycosis: A killer in the shadow of COVID-19
por: Suvvari, Tarun Kumar, et al.
Publicado: (2021)

Mitigating the Emerging Threat of Mucormycosis in COVID-19
por: Pothiawala, Sohil
Publicado: (2021)

COVID-19 and Rhino-Cerebral Mucormycosis: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Maxillary Mucormycosis Causing Oroantral Fistula in a Young Female
por: Saran, Sonal, et al.
Publicado: (2019)

Molecular Mechanisms of Antifungal Resistance in Mucormycosis
por: Ganesan, Priya, et al.
Publicado: (2022)

A toddler infected with mucormycosis – reporting the youngest case of mucormycosis in post COVID phase
por: Kubre, Jyotsna, et al.
Publicado: (2023)

Eyes Have It: From COVID-19 Perspective
por: Sarkar, Soumya, et al.
Publicado: (2020)

COVID-19 and Cannabis: Playing Saint or Devil?
por: Garg, Heena, et al.
Publicado: (2021)

Additional insights on COVID-associated mucormycosis
por: Panta, Prashanth
Publicado: (2022)

Mucormycosis—A serious threat in the COVID-19 pandemic?
por: Szarpak, Lukasz, et al.
Publicado: (2021)

Should statins be considered for the management of mucormycosis in COVID-19?
por: Chatterjee, Subhankar, et al.
Publicado: (2021)

COVID-19 associated mucormycosis - a recent challenge
por: dos Santos, Vitorino Modesto, et al.
Publicado: (2023)

Rise of the phoenix: Mucormycosis in COVID-19 times
por: Ravani, Swati A, et al.
Publicado: (2021)

In Pursuit of Freedom from COVID-19 Awareness in India: An Infodemiological Analysis
por: Sarkar, Soumya, et al.
Publicado: (2021)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

The Lay Contributor
Publicado: (1920)

Cannot write session to /tmp/vufind_sessions/sess_65jc5kf5svqesd2jin7pu74stk